Skip to main content

Nasdaq IPOs

Bancorp-led SPAC FTAC Athena Acquisition files for a $220 million IPO

5 years 8 months ago
FTAC Athena Acquisition, the seventh blank check company formed by management of The Bancorp to acquire a fintech business, filed on Wednesday with the SEC to raise up to $220 million in an initial public offering. The Philadelphia, PA-based company plans to raise $220 million b
Renaissance Capital

Phase 2 biotech Longeveron files for a $30 million IPO

5 years 8 months ago
Longeveron, a Phase 2 biotech developing cellular therapies for aging-related conditions, filed on Tuesday with the SEC to raise up to $30 million in an initial public offering. Longeveron is a clinical stage biotechnology company developing cellular therapies for specific aging
Renaissance Capital

French biotech Biophytis files for a $15 million US IPO

5 years 8 months ago
Biophytis, a French Phase 2 biotech developing therapies for COVID-related complications and age-related diseases, filed on Tuesday with the SEC to raise up to $15 million in an initial public offering. The company is currently listed on the Euronext Growth Paris (ALBPS). It
Renaissance Capital

Brazil-focused SPAC Itiquira Acquisition files for a $200 million IPO

5 years 8 months ago
Itiquira Acquisition, a blank check company targeting growth sectors in Brazil, filed on Tuesday with the SEC to raise up to $200 million in an initial public offering. The New York, NY-based company plans to raise $200 million by offering 20 million units at $10. Each unit will
Renaissance Capital

Immunotherapy biotech NexImmune files for an $86 million IPO

5 years 8 months ago
NexImmune, a Phase 1/2 biotech developing T cell immunotherapies for cancer, filed on Tuesday with the SEC to raise up to $86 million in an initial public offering. NexImmune is developing a novel approach to immunotherapy designed to employ the body's own T cells to generate a
Renaissance Capital

Chinese cancer biotech Adagene files for a $125 million US IPO

5 years 8 months ago
Adagene, a Phase 1 biotech developing antibody cancer immunotherapies in China, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering. Adagene is a platform-driven, clinical-stage biopharmaceutical company involved in the discovery and developme
Renaissance Capital
Checked
15 minutes 47 seconds ago
This feed is responsible for generating the rss feed related to the topic IPOs
Subscribe to Nasdaq IPOs feed